单位:[1]Chinese People’s Liberation Army General Hospital, Beijing, China[2]Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China[3]The First Affiliated Hospital of Haerbing Medical University, Haerbing, China[4]The First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[5]Yunnan Cardiovascular Hospital, Kunmin, China[6]Beijing Friendship Hospital, Capital Medical University, Beijing, China首都医科大学附属北京友谊医院[7]Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China[8]The First Hospital of Jilin University, Changchun, Jilin, China[9]General Hospital of Shenyang Military, Shenyang, China[10]The Second Hospital of Hebei Medical University, Shijiazhuang, China[11]Shanxi Da Hospital, Taiyuan, China[12]Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, United Kingdom[13]Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
BACKGROUND Low detection and nonadherence are major problems in current management approaches for patients with suspected atrial fibrillation (AF). Mobile health devices may enable earlier AF detection and improved AF management. OBJECTIVES This study sought to investigate the effectiveness of AF screening in a large population-based cohort using smart device-based photoplethysmography (PPG) technology, combined with a clinical care AF management pathway using a mobile health approach. METHODS AF screening was performed with smart devices using PPG technology, which were made available for the population >= 18 years of age across China. Monitoring for at least 14 days with a wristband (Honor Band 4) or wristwatch (Huawei Watch GT, Honor Watch, Huawei Technologies Co., Ltd., Shenzhen, China) was allowed. The patients with "possible AF" episodes using the PPG algorithm were further confirmed by health providers among the MAFA (mobile AF app) Telecare center and network hospitals, with clinical evaluation, electrocardiogram, or 24-h Holter monitoring. RESULTS There were 246,541 individuals who downloaded the PPG screening app, and 187,912 individuals used smart devices to monitor their pulse rhythm between October 26, 2018, and May 20, 2019. Among those with PPG monitoring (mean age 35 years, 86.7% male), 424 (of 187,912, 0.23%) (mean age 54 years, 87.0% male) received a "suspected AF" notification. Of those effectively followed up, 227 individuals (of 262, 87.0%) were confirmed as having AF, with the positive predictive value of PPG signals being 91.6% (95% confidential interval [CI]: 91.5% to 91.8%). Both suspected AF and identified AF markedly increased with age (p for trend <0.001), and individuals in Northeast China had the highest proportion of detected AF of 0.28% (95% CI: 0.20% to 0.39%). Of the individuals with identified AF, 216 (of 227, 95.1%) subsequently entered a program of integrated AF management using a mobile AF application; approximately 80% of high-risk patients were successfully anticoagulated. CONCLUSIONS Based on the present study, continuous home monitoring with smart device-based PPG technology could be a feasible approach for AF screening. This would help efforts at screening and detection of AF, as well as early interventions to reduce stroke and other AF-related complications. (Mobile Health [mHealth] Technology for Improved Screening, Patient Involvement and Optimizing Integrated Care in Atrial Fibrillation [MAFA II]; ChiCTR-OOC-17014138) (C) 2019 by the American College of Cardiology Foundation.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [H2501]; Health and Family Planning Commission of Heilongjiang Province, China [2017-036]; National Institute for Health Research Global Health Research Group on Atrial Fibrillation management at the University of Birmingham, United Kingdom
第一作者单位:[1]Chinese People’s Liberation Army General Hospital, Beijing, China
通讯作者:
通讯机构:[1]Chinese People’s Liberation Army General Hospital, Beijing, China[12]Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, United Kingdom[13]Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.[*1]Chinese PLA General Hospital, Department of Cardiology, No. 28, Fuxin Road, Beijing, 100853 China[*2]Liverpool Centre for Cardiovascular Science, William Henry Duncan Building, West Derby Street, Liverpool, Merseyside L7 8TX, United Kingdom
推荐引用方式(GB/T 7714):
Guo Yutao,Wang Hao,Zhang Hui,et al.Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation[J].JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY.2019,74(19):2365-2375.doi:10.1016/j.jacc.2019.08.019.
APA:
Guo Yutao,Wang Hao,Zhang Hui,Liu Tong,Liang Zhaoguang...&Lip Gregory Y H.(2019).Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation.JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY,74,(19)
MLA:
Guo Yutao,et al."Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation".JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY 74..19(2019):2365-2375